title: Massive pulmonary embolism after treatment with rFVIIa in a thrombocytopenic patient with acute myelogenous leukemia and intractable bleeding.
authors.forename: George
authors.initials: G
authors.lastname: Mantzios
authors.forename: Panagiotis
authors.initials: P
authors.lastname: Tsirigotis
authors.forename: Vassiliki
authors.initials: V
authors.lastname: Pappa
authors.forename: Konstantina
authors.initials: K
authors.lastname: Spirou
authors.forename: Vassiliki
authors.initials: V
authors.lastname: Giannopoulou
authors.forename: Irene
authors.initials: I
authors.lastname: Kaitsa
authors.forename: Konstantinos
authors.initials: K
authors.lastname: Girkas
authors.forename: Efstathios
authors.initials: E
authors.lastname: Papageorgiou
authors.forename: John
authors.initials: J
authors.lastname: Dervenoulas
mesh_terms: D000208:Acute Disease; D000368:Aged; D001803:Blood Transfusion; D003131:Combined Modality Therapy; D005167:Factor VII / Q000009:adverse effects* / Q000627:therapeutic use; D015942:Factor VIIa; D005260:Female; D005268:Femoral Vein; D005440:Fluid Therapy; D006471:Gastrointestinal Hemorrhage / Q000188:drug therapy*; D006490:Hemostatics / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D007951:Leukemia, Myeloid / Q000150:complications*; D011655:Pulmonary Embolism / Q000139:chemically induced*; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D016879:Salvage Therapy; D013920:Thrombocythemia, Essential / Q000150:complications*; D015912:Thrombolytic Therapy; D019851:Thrombophilia / Q000150:complications*; D013924:Thrombophlebitis / Q000139:chemically induced
chemical_list: D006490:Hemostatics; D011994:Recombinant Proteins; D005167:Factor VII; C103587:recombinant FVIIa; D015942:Factor VIIa